ACTA1 and metabolic dysfunction-associated steatohepatitis: Consistent with this observation, semi-quantitative analysis demonstrated that the α-SMA-positive area was significantly lower in the liver from myricetin-treated NASH mice than those from vehicle-treated animals (2.82 ± 0.15% vs. 5.15 ± 0.18%, P < 0.0001; Figure 3D).